Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Discovery of a ligand that compensates for decreased endogenous agonist potency of melanocortin-4 receptor polymorphisms identified in obese humans.

Haskell-Luevano C, Xiang Z, Wilczynski AM, Haskell KR, Andreasen AM, Litherland SA, Millard WJ, Pogozheva ID, Mosberg HI, Sorenson NB.

Adv Exp Med Biol. 2009;611:509-10. No abstract available.

PMID:
19400288
2.
3.

Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms.

Xiang Z, Pogozheva ID, Sorenson NB, Wilczynski AM, Holder JR, Litherland SA, Millard WJ, Mosberg HI, Haskell-Luevano C.

Biochemistry. 2007 Jul 17;46(28):8273-87. Epub 2007 Jun 23.

PMID:
17590021
4.

Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist.

Xiang Z, Litherland SA, Sorensen NB, Proneth B, Wood MS, Shaw AM, Millard WJ, Haskell-Luevano C.

Biochemistry. 2006 Jun 13;45(23):7277-88.

PMID:
16752916
5.
6.

Deletion of codons 88-92 of the melanocortin-4 receptor gene: a novel deleterious mutation in an obese female.

Donohoue PA, Tao YX, Collins M, Yeo GS, O'Rahilly S, Segaloff DL.

J Clin Endocrinol Metab. 2003 Dec;88(12):5841-5.

PMID:
14671178
7.

Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response.

Roubert P, Dubern B, Plas P, Lubrano-Berthelier C, Alihi R, Auger F, Deoliveira DB, Dong JZ, Basdevant A, Thurieau C, Clément K.

J Endocrinol. 2010 Nov;207(2):177-83. doi: 10.1677/JOE-09-0336. Epub 2010 Aug 9.

PMID:
20696697
8.

Melanocortin-4 receptor gene polymorphisms in obese patients.

Yurtcu E, Yilmaz A, Ozkurt Z, Kolukisa E, Yilmaz M, Keles H, Ergun MA, Yetkin I, Menevse A.

Biochem Genet. 2009 Apr;47(3-4):295-300. doi: 10.1007/s10528-009-9228-4. Epub 2009 Jan 31.

PMID:
19184404
9.

Identification of tetrapeptides from a mixture based positional scanning library that can restore nM full agonist function of the L106P, I69T, I102S, A219V, C271Y, and C271R human melanocortin-4 polymorphic receptors (hMC4Rs).

Haslach EM, Huang H, Dirain M, Debevec G, Geer P, Santos RG, Giulianotti MA, Pinilla C, Appel JR, Doering SR, Walters MA, Houghten RA, Haskell-Luevano C.

J Med Chem. 2014 Jun 12;57(11):4615-28. doi: 10.1021/jm500064t. Epub 2014 May 14.

10.

Melanocortin-4 receptor polymorphisms in Turkish pediatric obese patients.

Demiralp DO, Berberoglu M, Akar N.

Clin Appl Thromb Hemost. 2011 Feb;17(1):70-4. doi: 10.1177/1076029609354330. Epub 2010 Jun 7.

PMID:
20530052
11.

Identification and functional characterization of three novel human melanocortin-4 receptor gene variants in an obese Chinese population.

Rong R, Tao YX, Cheung BM, Xu A, Cheung GC, Lam KS.

Clin Endocrinol (Oxf). 2006 Aug;65(2):198-205.

PMID:
16886960
12.

Synthesis, biophysical, and pharmacological evaluation of the melanocortin agonist AST3-88: modifications of peptide backbone at Trp 7 position lead to a potent, selective, and stable ligand of the melanocortin 4 receptor (MC4R).

Singh A, Dirain ML, Wilczynski A, Chen C, Gosnell BA, Levine AS, Edison AS, Haskell-Luevano C.

ACS Chem Neurosci. 2014 Oct 15;5(10):1020-31. doi: 10.1021/cn5000953. Epub 2014 Aug 26.

13.

Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism.

Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard WJ, Mosberg HI, Haskell-Luevano C.

Chem Biol Drug Des. 2006 Mar;67(3):215-29.

14.

Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function.

Govaerts C, Srinivasan S, Shapiro A, Zhang S, Picard F, Clement K, Lubrano-Berthelier C, Vaisse C.

Peptides. 2005 Oct;26(10):1909-19. Review.

PMID:
16083993
15.

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.

Nargund RP, Strack AM, Fong TM.

J Med Chem. 2006 Jul 13;49(14):4035-43. Review. No abstract available.

PMID:
16821763
17.

Effect of interactions of polymorphisms in the Melanocortin-4 receptor gene with dietary factors on the risk of obesity and Type 2 diabetes: a systematic review.

Koochakpoor G, Hosseini-Esfahani F, Daneshpour MS, Hosseini SA, Mirmiran P.

Diabet Med. 2016 Aug;33(8):1026-34. doi: 10.1111/dme.13052. Epub 2016 Feb 5. Review.

PMID:
26666384
18.

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.

Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT.

Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8.

19.

Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.

Hong Q, Bakshi RK, Palucki BL, Park MK, Ye Z, He S, Pollard PG, Sebhat IK, Liu J, Guo L, Cashen DE, Martin WJ, Weinberg DH, MacNeil T, Tang R, Tamvakopoulos C, Peng Q, Miller RR, Stearns RA, Chen HY, Chen AS, Strack AM, Fong TM, MacIntyre DE, Wyvratt MJ, Nargund RP.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2330-4. doi: 10.1016/j.bmcl.2011.02.090. Epub 2011 Mar 1.

PMID:
21439820
20.

Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.

Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Sorensen NB, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C.

J Med Chem. 2004 Apr 22;47(9):2194-207.

PMID:
15084118

Supplemental Content

Support Center